Shares of ResMed Inc. (NYSE:RMD) have received a consensus rating of “Hold” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $61.00.

A number of equities research analysts recently issued reports on RMD shares. BidaskClub cut shares of ResMed from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research report on Thursday, July 6th. Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. BMO Capital Markets reiterated a “hold” rating on shares of ResMed in a research report on Friday, May 12th. Finally, Credit Suisse Group cut shares of ResMed from an “outperform” rating to a “neutral” rating in a research report on Wednesday, August 2nd.

ResMed (NYSE:RMD) traded up 0.38% on Friday, reaching $73.07. 529,536 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $75.98 and a 200-day moving average of $72.38. ResMed has a 12 month low of $56.59 and a 12 month high of $79.63. The firm has a market capitalization of $10.39 billion, a price-to-earnings ratio of 30.45 and a beta of 0.83.

ResMed (NYSE:RMD) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.02. The business had revenue of $556.69 million during the quarter, compared to analysts’ expectations of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the company posted $0.74 EPS. On average, equities analysts expect that ResMed will post $3.03 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be issued a dividend of $0.35 per share. The ex-dividend date is Tuesday, August 15th. This represents a $1.40 dividend on an annualized basis and a yield of 1.92%. This is a positive change from ResMed’s previous quarterly dividend of $0.33. ResMed’s dividend payout ratio is currently 58.09%.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $71.02, for a total transaction of $88,775.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard Sulpizio sold 65,887 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $77.82, for a total transaction of $5,127,326.34. Following the sale, the director now directly owns 4,429 shares in the company, valued at approximately $344,664.78. The disclosure for this sale can be found here. In the last three months, insiders have sold 204,650 shares of company stock worth $15,516,845. Insiders own 1.97% of the company’s stock.

A number of large investors have recently modified their holdings of the company. Toronto Dominion Bank raised its stake in shares of ResMed by 26.6% in the first quarter. Toronto Dominion Bank now owns 1,543 shares of the medical equipment provider’s stock worth $111,000 after buying an additional 324 shares in the last quarter. YorkBridge Wealth Partners LLC raised its stake in shares of ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 69 shares in the last quarter. Creative Planning raised its stake in shares of ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after buying an additional 823 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of ResMed by 7.5% in the first quarter. Van ECK Associates Corp now owns 1,945 shares of the medical equipment provider’s stock worth $140,000 after buying an additional 136 shares in the last quarter. Finally, Huntington National Bank bought a new stake in shares of ResMed during the second quarter worth approximately $156,000. 60.66% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ResMed Inc. (RMD) Receives Average Rating of “Hold” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/18/resmed-inc-rmd-receives-average-rating-of-hold-from-analysts.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.